Researchers from the Johns Hopkins University School of Medicine have found that type 2 helper T cells played an important supportive role in scaffold-aided tissue regeneration after injury. Read More

Braeburn Pharmaceuticals Inc., of Princeton, N.J., presented data from a phase III study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, showing that participants who were clinically stable on sublingual buprenorphine maintained stability when transferred to Probuphine and they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine. Data were presented at the American Society of Addiction Medicine conference in Baltimore. Probuphine is under FDA review, with a PDUFA date of May 27. Read More

Carbylan Therapeutics Inc., of Palo Alto, Calif., said it suspended clinical development of Hydros-TA, its formulation of hyaluronic acid to treat pain associated with osteoarthritis of the knee, and is pursuing a strategic transaction, including a merger or acquisition of the company. The company reduced its work force from 17 employees to three and said it expects to have about $25 million to $30 million of net cash available for a potential strategic transaction. Read More

Gensight Biologics SA, of Paris, withdrew its proposed IPO because of market conditions. The deal would have sought to raise $65 million by offering 4.7 million shares at a price range of $13 to $15. Read More

Having worked in academia, big pharma and venture capital, Naia Ltd. co-founder H. Daniel Perez got to witness drug development from three different perspectives, and he came away with one conclusion: "It was very clear things were not being done efficiently," he said. Read More

HONG KONG – Researchers at the National Institute for Physiological Sciences (NIPS) in Okazaki, Japan, have identified events in the primary sensory (S1) cortex of the brain that contribute to sustained mechanical allodynia and may represent a new therapeutic target for pain relief, they reported in the April 11, 2016, edition of the Journal of Clinical Investigation. Read More

With about 5.4 million people suffering from Alzheimer's disease in the U.S. and 44 million worldwide, and with populations in developed countries living longer, the search for effective therapies is becoming ever more urgent. Analysts at J.P. Morgan call AD "one of the most attractive potential new categories in major pharma and biotech," with the potential for more than $10 billion in peak sales for a drug that works. A new report by the firm pegs "a number of key catalysts" this year, and anticipates that investors' focus on AD will increase as 2016 wears on. Read More

Renewed excitement over signs that RG-101, a microRNA-122 antagonist from Regulus Therapeutics Inc., could shorten the duration of several direct-acting antiviral (DAA) treatment regimens for hepatitis C virus (HCV) to as little as four weeks boosted company shares (NASDAQ:RGLS) briefly on Friday before giving way to concerns about whether the cure it delivers will persist over time, sending shares down 11 percent to close at $7.23. Read More

Enthusiasm for bispecific antibodies has anything but abated since late 2014, when the FDA granted accelerated approval of Amgen Inc.'s Blincyto (blinatumomab) for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL). Read More